Hampton, Va.-based ivWatch announced the launch of its ivWatch OEM board designed to enable seamless integration of its IV infiltration detection technology with patient monitoring systems, infusion pumps and other devices.
OEMs can help bring a higher level of patient care to patients and reduce risks that come from IV therapies by using ivWatch technology in existing products.
“The ivWatch OEM Board provides a way to leverage existing ivWatch technology and sensors and integrate them into the OEMs’ products and bring the benefits of real-time monitoring to more hospitals,” Gary P. Warren, president and CEO of ivWatch, said in a press release.
“This new OEM solution is a natural extension of our mission of advancing patient safety, and we’re excited to work with global partners to make it a reality,” Warren said.
IV therapy is the process of administering liquids directly into the vein. Infiltration occurs when a needle is placed incorrectly and liquids infuse outside of the intravascular space, according to Columbia University.
ivWatch is the first technology that can continuously monitor an IV site while determining if drugs are being delivered to the vein without any leakage. The OEM Board makes it easier for ivWatch to put its technology in other devices so clinicians can catch IV infiltrations sooner.
The company is also expanding its executive team. ivWatch recently brought on Scott Hensley as the VP of sales, who previously served as the VP of sales for 13 years at the biosensor company Masimo. The company has also appointed Melissa Fire as the leader of the OEM initiative and VP of global strategy and business development after having served as the VP of sales.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]
